Launch of the Saliva Pregnancy self-test in Boots

Abingdon Health PLC

15 May 2024

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Abingdon Health plc

("Abingdon Health" or "the Company")

Launch of the Saliva Pregnancy self-test in Boots

·    Boots will be the first retailer to sell the world's first saliva pregnancy self-test under its own brand label

·    Tests will be available in Boots stores and online across the UK provided by Abingdon Health, Salignostics and Crest Medical partnership

York, U.K. 15th May 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow Contract Development and Manufacturing Organisation (CDMO), announces the launch of Boots own-brand, saliva pregnancy self-test across the UK and online, in partnership with Salignostics and Crest Medical.

On 20^th March 2024, Abingdon Health announced the launch of the first two Boots branded self-tests - Iron and Vitamin D deficiency - in-store and online at boots.com.

In another step toward strengthening this partnership with Boots, Abingdon Health is now pleased to announce the launch of the first ever saliva pregnancy test under the Boots own brand range. The test is being made available in store and online at boots.com from Spring 2024 onwards. This product launch allows more people to access a new way of testing for pregnancy.

With the UK pregnancy self-test market expected to reach USD $56.7 million by 2033¹, this provides a strategic opportunity to launch, on an own-brand basis, an innovative product in this growing market with the UK's leading health and beauty retailer. With general consumer adoption of self-tests on the rise (US $7.89 billion in 2023)², and a robust pipeline of products within its CRO/CDMO offering, Abingdon Health is well positioned to continue developing OEM retail relationships within the UK and Europe as a value-add, innovative Private Label Supplier (PLS).

Chris Yates, CEO of Abingdon Health plc, commented: "We are delighted to announce the launch of the Boots branded saliva pregnancy test in conjunction with our partners Salignostics and Crest Medical. This launch showcases our ability to deliver innovative and disruptive private label products through our CDMO/CRO lateral flow full-service proposition with one of the most trusted UK brands - Boots."

Guy Krief, Co-Founder and Deputy CEO of Salignostics Ltd, commented: "We are delighted to partner on this exciting opportunity for our breakthrough technology that has brought the first ever saliva pregnancy test to market. Boots is the leading health and beauty retailer in the UK and offering our saliva pregnancy test under their own brand label will drive consumer education, confidence and adoption of the platform."

Matthew Courtney, CEO of Crest Medical Ltd, commented: "After the recent release of Vitamin D and Iron deficiency testing under the Boots family of products, the launch of the saliva pregnancy test is another terrific step forwards in expanding our portfolio and deepening our partnership with Abingdon Health."

Sources:

1.     https://www.futuremarketinsights.com/reports/at-home-pregnancy-testing-market

2.     Self-testing Market Share, Growth, Demand, Forecast to 2033 (futuremarketinsights.com)

Enquiries

Abingdon Health plc	www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer
Chris Hand, Non-Executive Chairman
WH Ireland Limited (Sole Broker and Nominated Adviser)	Tel: [phone]
Chris Fielding / Isaac Hooper (Corporate Finance)
Fraser Marshall (Corporate Broking)

The person responsible for arranging the release of this announcement on behalf of the Company is Chris Yates, Chief Executive Officer of the Company.

About Abingdon Health plc

Abingdon Health is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".

The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations; and produces lateral flow tests in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making and targeted intervention; and can support better outcomes. 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

 

END